ABT

The company traces to a young Chicago physician. In 1888 Wallace Calvin Abbott, a doctor frustrated by the inconsistent potency of the medicines available to him, began producing precise doses of plant-based alkaloids from his apartment in the Ravenswood neighborhood, founding what he called the Abbott Alkaloidal Company. The premise was quality control. Where competitors sold crude extracts of uneven strength, Abbott offered measured, repeatable doses a physician could trust, and that reputation for reliability seeded a manufacturing business. The firm was renamed Abbott Laboratories in 1915, went public in 1929, and over the following century expanded well beyond medicines into infant formula, hospital products, diagnostic testing, and medical hardware, growing through both internal development and a long series of acquisitions. The defining structural decision of the modern era came on the first day of 2013, when Abbott separated its research-based branded pharmaceutical operations into a new public company, AbbVie, and handed AbbVie shares to its own shareholders. What remained under the Abbott name was deliberately broad, a healthcare company with no single product capable of sinking it and no looming patent cliff of the kind that defines the branded drug industry.

The structure that matters today is four reporting segments, and the balance among them is the point. Medical Devices is the largest and fastest-growing of the four. It spans diabetes care, cardiovascular intervention, heart rhythm management, neuromodulation, and structural heart products, selling hardware and consumables to clinicians and, increasingly, directly to patients. Diagnostics develops and sells the instruments and tests used in hospital laboratories, blood screening operations, and at the point of care, a business that scaled dramatically during the pandemic on COVID testing and has since normalized to its underlying core. Established Pharmaceuticals is unusual and easy to misread. It does not sell patent-protected drugs in wealthy markets. Instead it sells branded generic medicines almost entirely in emerging markets such as India, China, Russia, Brazil, and across Latin America and Southeast Asia, where a trusted brand name carries real weight with patients and physicians. Nutrition rounds out the portfolio with infant formula under the Similac name and adult nutrition products under Ensure and Glucerna. The four businesses share little operationally, since a device factory, a diagnostics instrument, a generic-drug supply chain, and a formula plant run on different timelines and different sales motions, but they share the balance sheet, the brand, and a diversification logic that has defined Abbott for generations.

That diversification is the heart of the investment case and the source of the company's durability. Healthcare demand is relatively insensitive to the economic cycle, since people need testing, treatment, and nutrition regardless of recessions, and Abbott spreads its exposure across four businesses, dozens of product lines, and most of the countries on earth so that no single setback sinks the whole. A soft quarter in diagnostics can be offset by strength in devices, a regulatory delay in one market by growth in another, the maturation of one product by the launch of the next. The breadth itself is a moat, but it is reinforced by scale advantages that are specific to each segment. In medical devices, regulatory approval, clinical evidence, and physician trust take years and large sums to build, which protects incumbents and punishes thinly funded challengers. In diagnostics, an installed base of laboratory instruments locks in years of recurring reagent and test revenue, since hospitals rarely rip out a platform once their workflows depend on it. In emerging-market generics, a trusted brand commands a price premium over identical unbranded molecules. In nutrition, the Similac and Ensure names carry decades of consumer recognition. Abbott reinvests steadily into this portfolio, funding research, manufacturing capacity, and acquisitions, which is how a company well over a century old keeps refreshing its product line without depending on the boom-and-bust patent cycle of branded pharma.

The single most important growth engine is the FreeStyle Libre, and it deserves to be understood on its own. Continuous glucose monitoring replaces the old routine of pricking a finger several times a day with a small sensor worn on the arm that reads glucose continuously and sends the data to a phone or reader. Abbott built the category for affordability and scale, pricing the Libre to reach not only the relatively small population of insulin-dependent type 1 diabetics but the far larger population of type 2 diabetics and, increasingly, people who simply want to understand how their bodies respond to food and exercise. The strategy has worked. As of 2025 the Libre franchise generated more than seven and a half billion dollars in annual sales and had added more than a billion dollars of incremental revenue for several years running, making it one of the most successful medical devices ever commercialized. The sensors are consumables replaced every couple of weeks, which converts each new user into a recurring revenue stream rather than a one-time sale. This is the franchise that most clearly distinguishes Abbott from a slow-growing healthcare conglomerate, and it anchors the broader case that the device segment can compound at double-digit rates for years.

Competition is intense and specific to each segment rather than companywide. In continuous glucose monitoring, the primary rival is Dexcom, which competes hard on sensor accuracy and features, with Medtronic a distant third, and the two leaders together hold the large majority of a market that is still expanding as monitoring spreads beyond insulin users. Abbott has generally held the larger share by volume on the strength of price and breadth, while Dexcom has pushed on premium performance. In diagnostics, Abbott contends with Roche, Siemens Healthineers, and Danaher, all running their own installed bases of laboratory instruments. In cardiovascular and structural heart devices, the field includes Medtronic, Boston Scientific, Edwards Lifesciences, and Johnson & Johnson, each strong in particular niches. In nutrition, the infant formula business competes with Reckitt and Nestle. In emerging-market generics, the competition is fragmented and local. Abbott tends to win on the combination of breadth, price discipline, and the strength of individual platforms such as the Libre rather than by dominating every category it touches.

Leadership sits with Robert Ford, who became chief executive at the end of March 2020, just as the pandemic began, and later added the chairman title. Ford is a long-tenured insider who rose through the medical device side of the company, including its diabetes business, before reaching the top job, and his tenure has been defined by leaning into devices in general and the Libre in particular while managing the company through the extraordinary swing of pandemic-era testing demand and its subsequent normalization. The approach has been steady rather than transformational. Push capital toward the fastest-growing device franchises, defend the diagnostics installed base, harvest the cash-generative nutrition and established-pharmaceuticals segments, and let the diversified structure compound. That steadiness is reflected in one of the most distinctive facts about the company. Abbott has raised its dividend for more than fifty consecutive years, a record that places it among the so-called Dividend Kings and that spans decades of recessions, market crashes, and the AbbVie separation, when the two companies together continued the streak. For many shareholders that uninterrupted record is the core of why they own the stock.

The forward strategy is more of the same, sharpened. Abbott continues to invest in expanding the Libre into adjacent uses, including sensors aimed at people without diabetes and combination products that pair glucose monitoring with other measurements, and it continues to build out its structural heart and electrophysiology device lines, areas where an aging population drives durable demand. The diagnostics business is being managed back to steady core growth now that pandemic testing has faded, and the company keeps extending its emerging-market footprint where rising incomes expand access to branded medicines and quality nutrition. The bet is that a balanced, globally distributed healthcare company anchored by a category-defining device franchise can grow faster than its mature size would suggest, without taking on the binary risk of a branded-drug pipeline.

The risks are real and worth naming specifically. The largest near-term legal exposure is litigation alleging that Abbott's specialized formula for premature infants caused necrotizing enterocolitis, a serious intestinal condition, with cases consolidated in federal and state courts. Jury outcomes through 2025 and into 2026 have been mixed, with some verdicts against the company reaching into the tens of millions of dollars and other cases dismissed, and the ultimate aggregate cost is genuinely uncertain because it depends on trials and appeals that no one can confidently forecast. Beyond that, Abbott carries the ordinary risks of its industry. Device approval and reimbursement decisions can be delayed or denied by regulators and insurers. Continuous glucose monitoring, while growing, faces relentless competitive and pricing pressure as rivals improve their sensors. A large share of revenue comes from outside the United States, which exposes results to currency swings and to political and economic instability in emerging markets. And the diagnostics business has had to absorb the difficult comparison of a multibillion-dollar pandemic testing windfall that has since receded.

The way to weigh Abbott Laboratories is as a trade between stability and ceiling. The company has assembled a genuinely diversified healthcare franchise across four loosely related businesses, a structure that smooths the cycle and that has carried a dividend through more than fifty consecutive years of raises, and it owns in the FreeStyle Libre one of the rare medical devices capable of compounding at high rates for a sustained stretch. That same breadth and maturity also limit how fast the whole can move, since a soft segment dilutes a strong one and a company of this size cannot grow like a single-product upstart. Layered on top is the infant-formula litigation, an open-ended liability that resists clean estimation. The central question for an investor is whether the steadiness of a balanced, globally distributed healthcare leader, paced by the growth of its glucose-monitoring franchise, is worth holding through a legal overhang whose final cost remains unknown, and whether the device engine can keep lifting the company's overall growth rate above what its diversified, mature base would otherwise deliver.